Prospective, Post Market Surveillance Q3-registry (POLARIS) (Q3-Registry)
Prospective, Non-randomized Post Market Surveillance Registry to Document the Clinical Performance in Routine Clinical Practice of the POLARIS Peripheral Vascular Self Expanding Stent System.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Sigrid Krimmer-Quendler, PhD
- Phone Number: +40417165780
- Email: quendler@qualimed.de
Study Locations
-
-
-
Bad Bevensen, Germany, 29549
- Recruiting
- HGZ Bad Bevensen, Department of Angiology
-
Contact:
- Hans Krankenberg, MD, PhD
- Phone Number: +495821821157
- Email: h.krankenberg@hgz-bb.de
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Age >18 years
- Single target de novo superficial femoral artery lesion (angiographic evidence of >50% Stenosis or occlusion) by visual estimate
- Rutherford category II-IV
- At least one patent outflow artery to the ankle.
- Patient signed the informed consent
Exclusion Criteria:
- Patient with acute or subacute Thrombus
- Patients with hyperkoagulopathy
- Patients with Stenosis or occlusion where lesion crossing with guide wire is not possible
- Pregnancy or positive pregnancy test
- Previous enrolment in this Trial or other industrial Trials
- Patient´s inability to fully cooperate with the registry protocol Patient with cancer Treatment (life expectancy less than 2 years) Patients with renal failure
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Freedom from target lesion revascularization
Time Frame: at 12 months
|
Clinically driven
|
at 12 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Binary restenosis/ reocclusion
Time Frame: at 12 months
|
Defined as peak systolic velocity tatio (PSVR) > 2.4
|
at 12 months
|
|
Target limb amputation at the index leg (major and minor separately)
Time Frame: at 12 months
|
at 12 months
|
|
|
All-cause death
Time Frame: at 12 months
|
at 12 months
|
|
|
Change in resting ankle brachial index (ABI)
Time Frame: From baseline to 12 and 24 months
|
From baseline to 12 and 24 months
|
|
|
Change in Rutherford Classification
Time Frame: From baseline to 12 and 24 months
|
From baseline to 12 and 24 months
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Hans Krankenberg, MD,PhD, Cardiovascular Center Bad Bevensen, Department of Angiology
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- QualiMed
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.